Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer

• Status: Unknown status
• Trial end date: 2020-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The researchers investigated the rate of biochemical remission in patients without radioactive iodine therapy compared to patients with low dose radioactive iodine treatment in differentiated thyroid cancer patients who underwent total thyroidectomy.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Center, Korea
• Treatments: Iodine

Criteria

Inclusion Criteria:

• patients with differentiated thyroid cancer

• recently underwent total thyroidectomy (within 6 months)

• pathological criteria

1. T1bN0 : Tumor size 1-2cm with no microscopic extension with multifocality (within three foci)

2. T3N0 : Tumor size <=2cm with microscopic extension (less than strap muscle)

3. T1-3N1a : 3 or less micrometastatic lymph node

Exclusion Criteria:

• differentiated thyroid cancer with aggressive variant, poorly differentiated thyroid cancer, medullary thyroid cancer, anaplastic thyroid cancer

• gross extension (strap muscle or more)

• thyroid cancer with distant metastasis

• previous remote history of thyroid cancer surgery

• history of cervical external beam radiation therapy

• previous history of comorbid cancer within 5 years

• renal insufficiency (Ccr <30ml/min)

• women with pregnancy or breast feeding